Cepharanthine
Cepharanthine is an antiinflammatory and antineoplastic compound isolated from Stephania.[1] Due to these modalities, it has been shown effective against HTLV in lab research. [2] Additionally, it has successfully been used to treat a diverse range of medical conditions, including radiation-induced leukopenia, idiopathic thrombocytopenic purpura, alopecia areata, alopecia pityrodes, venomous snakebites, xerostomia, sarcoidosis, refractory anemia and various cancer-related conditions. No safety issues have been observed with CEP, and side effects are very rarely reported. [3]
 | |
| Clinical data | |
|---|---|
| Other names | Cepharantin, O-Methylcepharanoline |
| AHFS/Drugs.com | International Drug Names |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.208.632  |
| Chemical and physical data | |
| Formula | C37H38N2O6 |
| Molar mass | 606.719 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
References
- Huang H, Hu G, Wang C, Xu H, Chen X, Qian A (February 2014). "Cepharanthine, an alkaloid from Stephania cepharantha Hayata, inhibits the inflammatory response in the RAW264.7 cell and mouse models". Inflammation. 37 (1): 235–46. doi:10.1007/s10753-013-9734-8. PMID 24045962. S2CID 7186762.
- Toyama M, Hamasaki T, Uto T, Aoyama H, Okamoto M, Hashmoto Y, Baba M (July 2012). "Synergistic inhibition of HTLV-1-infected cell proliferation by combination of cepharanthine and a tetramethylnaphthalene derivative". Anticancer Research. 32 (7): 2639–45. PMID 22753721.
- Rogosnitzky M, Danks R (2011). "Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions" (PDF). Pharmacological Reports. 63 (2): 337–47. doi:10.1016/S1734-1140(11)70500-X. PMID 21602589.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.